CN113694047A - β-石竹烯在制备抗肿瘤药物中的应用 - Google Patents
β-石竹烯在制备抗肿瘤药物中的应用 Download PDFInfo
- Publication number
- CN113694047A CN113694047A CN202111012109.3A CN202111012109A CN113694047A CN 113694047 A CN113694047 A CN 113694047A CN 202111012109 A CN202111012109 A CN 202111012109A CN 113694047 A CN113694047 A CN 113694047A
- Authority
- CN
- China
- Prior art keywords
- caryophyllene
- beta
- gefitinib
- cells
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- NPNUFJAVOOONJE-ZIAGYGMSSA-N β-(E)-Caryophyllene Chemical compound C1CC(C)=CCCC(=C)[C@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-ZIAGYGMSSA-N 0.000 title claims abstract description 136
- NPNUFJAVOOONJE-UHFFFAOYSA-N beta-cariophyllene Natural products C1CC(C)=CCCC(=C)C2CC(C)(C)C21 NPNUFJAVOOONJE-UHFFFAOYSA-N 0.000 title claims abstract description 69
- NPNUFJAVOOONJE-UONOGXRCSA-N caryophyllene Natural products C1CC(C)=CCCC(=C)[C@@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-UONOGXRCSA-N 0.000 title claims abstract description 67
- 239000002246 antineoplastic agent Substances 0.000 title claims abstract description 11
- 229940041181 antineoplastic drug Drugs 0.000 title claims abstract description 9
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims abstract description 38
- 229960002584 gefitinib Drugs 0.000 claims abstract description 38
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims abstract description 38
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 abstract description 40
- 229940079593 drug Drugs 0.000 abstract description 20
- 239000003814 drug Substances 0.000 abstract description 20
- 230000005764 inhibitory process Effects 0.000 abstract description 15
- 206010028980 Neoplasm Diseases 0.000 abstract description 13
- 208000002154 non-small cell lung carcinoma Diseases 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 11
- 206010059866 Drug resistance Diseases 0.000 abstract description 9
- 230000002441 reversible effect Effects 0.000 abstract description 8
- 230000012010 growth Effects 0.000 abstract description 5
- 210000004881 tumor cell Anatomy 0.000 abstract description 4
- 238000002360 preparation method Methods 0.000 abstract description 3
- 230000035755 proliferation Effects 0.000 abstract description 3
- 206010067484 Adverse reaction Diseases 0.000 abstract description 2
- 206010070834 Sensitisation Diseases 0.000 abstract description 2
- 230000006838 adverse reaction Effects 0.000 abstract description 2
- 229940044683 chemotherapy drug Drugs 0.000 abstract description 2
- 230000008313 sensitization Effects 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 230000004565 tumor cell growth Effects 0.000 abstract description 2
- NVEQFIOZRFFVFW-UHFFFAOYSA-N 9-epi-beta-caryophyllene oxide Natural products C=C1CCC2OC2(C)CCC2C(C)(C)CC21 NVEQFIOZRFFVFW-UHFFFAOYSA-N 0.000 description 15
- FAMPSKZZVDUYOS-UHFFFAOYSA-N alpha-Caryophyllene Natural products CC1=CCC(C)(C)C=CCC(C)=CCC1 FAMPSKZZVDUYOS-UHFFFAOYSA-N 0.000 description 15
- 229940117948 caryophyllene Drugs 0.000 description 15
- 238000011282 treatment Methods 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 5
- 241000699660 Mus musculus Species 0.000 description 4
- 229940121647 egfr inhibitor Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000011580 nude mouse model Methods 0.000 description 4
- 230000005778 DNA damage Effects 0.000 description 3
- 231100000277 DNA damage Toxicity 0.000 description 3
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 3
- 101000911513 Homo sapiens Uncharacterized protein FAM215A Proteins 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 3
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 3
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 3
- 102100026728 Uncharacterized protein FAM215A Human genes 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 101710179684 Poly [ADP-ribose] polymerase Proteins 0.000 description 2
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 2
- 231100000753 hepatic injury Toxicity 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 102200048955 rs121434569 Human genes 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102000009135 CB2 Cannabinoid Receptor Human genes 0.000 description 1
- 108010073376 CB2 Cannabinoid Receptor Proteins 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 1
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
- 241000218228 Humulus Species 0.000 description 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
- 235000013628 Lantana involucrata Nutrition 0.000 description 1
- 244000178870 Lavandula angustifolia Species 0.000 description 1
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 1
- 235000006677 Monarda citriodora ssp. austromontana Nutrition 0.000 description 1
- 235000010676 Ocimum basilicum Nutrition 0.000 description 1
- 240000007926 Ocimum gratissimum Species 0.000 description 1
- 240000007673 Origanum vulgare Species 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 244000203593 Piper nigrum Species 0.000 description 1
- 235000008184 Piper nigrum Nutrition 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 1
- 244000063464 Vitex agnus-castus Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000002616 bicyclic sesquiterpene group Chemical group 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 235000013614 black pepper Nutrition 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000009120 camo Nutrition 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- 235000009347 chasteberry Nutrition 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000001734 eugenia caryophyllata l. bud oleoresin Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000011487 hemp Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000001102 lavandula vera Substances 0.000 description 1
- 235000018219 lavender Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000000014 opioid analgesic Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008261 resistance mechanism Effects 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明公开β‑石竹烯在制备抗肿瘤药物中的应用。本发明提出β‑石竹烯对肿瘤细胞生长的抑制作用，并且表明β‑石竹烯能够逆转NSCLC吉非替尼耐药。本发明提出吉非替尼与β‑石竹烯联用能产生较好的协同增敏效果，能够极大程度上克服肿瘤细胞对化疗药物的耐药性。本发明对于如何减缓或逆转吉非替尼对NSCLC细胞的耐药性，减缓肿瘤的生长增值速度，减少甚至逆转吉非替尼药物的不良反应，改善NSCLC患者的临床均具有重要的意义。
Description
技术领域
本发明属于制药领域，涉及β-石竹烯在制备抗肿瘤药物中的应用，以及β-石竹烯和吉非替尼药物配伍组合物在制备抗肿瘤药物中的应用。
背景技术
癌症被认为是世界上每个国家的主要死亡原因和延长预期寿命的重要障碍。据世界卫生组织(WHO)2019年的估计，在183个国家中的112个国家中年龄为70岁之前癌症是人类第一或第二大死亡原因。总体而言，世界范围内的癌症发病率和死亡率的负担正在迅速增长。预计到2040年全球将发生2840万例新癌症病例，比2020年的1930万例增加47％。总体而言，世界范围内癌症发病率和死亡率的负担正在迅速增长。
β-石竹烯(BCP)是一种双环倍半萜型天然化合物，有α-，β-，γ-三种异构体，β-石竹烯的双键顺式异构体称为异石竹烯(isocarophyllene),国家标准GB2760-2014批准石竹烯为允许使用的食品香料。β-石竹烯英文通用名称β-Caryophyllene，分子量为204.36，其性状为无色至微黄油状液体，具有淡的丁香似香味。沸点119-121℃。β-石竹烯(BCP)是罗勒、黑胡椒、薰衣草、迷迭香、牛至、啤酒花、大麻、肉桂叶油、丁香叶油、牡荆油、陈皮油等的挥发油中主要活性成分之一。β-石竹烯的化学结构式如下：
β-石竹烯具有多种药理作用，其可减少炎症过程中促炎性细胞因子形成、降低Akt、环氧化酶的蛋白表达产生抗炎作用；可通过兴奋CB2受体及激活内源性阿片镇痛系统发挥镇痛作用；通过激动脊髓等中枢系统的CB受体,减轻脑缺血再灌注损伤，对神经变性疾病具有神经保护作用；可通过抑制肝HMG-CoA还原酶活性、下调TLR4和RAGE信号等途经减轻肝损伤、保护肝脏免受脂质损伤。BCP对多种肿瘤细胞具有细胞毒性，但关于BCP抗肿瘤作用机制尚不明确。
现有研究提示，石竹烯的药理作用具有抗炎，镇痛，神经保护，防止肝损伤，抗血糖，调节血脂等方面的应用，尚未见有抗肿瘤方面的报道。
表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)是一种特异性的EGFR酪氨酸激酶抑制剂，通过竞争性地抑制ATP与受体胞内区结合，从而抑制酪氨酸激酶活化，阻断EGFR的传导通路，达到抗肿瘤治疗的目的。
吉非替尼作为一种选择性表皮生长因子受体酪氨酸激酶抑制剂类靶向药物，被广泛应用于NSCLC的临床治疗并取得了良好的疗效，但频繁出现的耐药现象限制了其进一步的发展。其中，EGFR T790M突变是最常见的获得性耐药机制。在临床肺癌治疗中，EGFR活化突变的NSCLC患者中可检测到多达50％的EGFR T790M突变。因此，在体外进行肺癌细胞耐药机制的探索，乃至寻找能够逆转肿瘤细胞耐药的药物是目前研究的要点。
发明内容
本发明的第一个目的是针对现有技术的不足，提供β-石竹烯在制备抗肿瘤药物中的应用。
本发明的第二个目的是针对现有技术的不足，提供β-石竹烯与吉非替尼配伍的药物组合物在制备抗肿瘤药物中的应用。
本发明的第三个目的是一种药物组合物，包括β-石竹烯、吉非替尼、药剂学上可接受的辅料。
作为优选，β-石竹烯与吉非替尼的质量比为75～100：10。
所述的β-石竹烯可以采用常规的方法从天然植物中提取，也可以由合成或其他方法制得。β-石竹烯的纯度为90％。
本发明的有益效果：
本发明提出β-石竹烯对肿瘤细胞生长的抑制作用，并且表明β-石竹烯能够逆转NSCLC吉非替尼耐药。本发明提出吉非替尼与β-石竹烯联用能产生较好的协同增敏效果，能够极大程度上克服肿瘤细胞对化疗药物的耐药性。本发明对于如何减缓或逆转吉非替尼对NSCLC细胞的耐药性，减缓肿瘤的生长增值速度，减少甚至逆转吉非替尼药物的不良反应，改善NSCLC患者的临床均具有重要的意义。
附图说明
图1是HCC827细胞对不同浓度石竹烯药物的抑制率。
图2是SW-1990细胞对不同浓度石竹烯药物的抑制率。
图3是MDA-231细胞对不同浓度石竹烯药物的抑制率。
图4是HCT-116细胞对不同浓度石竹烯药物的抑制率。
图5是U251细胞对不同浓度石竹烯药物的抑制率。
图6是PC9细胞对不同浓度石竹烯药物的抑制率。
图7是对照组、吉非替尼处理组、β-石竹烯处理组和吉非替尼和β-石竹烯联合处理组下异种移植瘤的肿瘤生长曲线。
图8是四组处理组检测凋亡相关蛋白PARP,Bcl-2,mTOR蛋白，以及DNA损伤相关蛋白的表达，其中对照组记为组A、吉非替尼处理组记为组B、β-石竹烯处理组记为组C、吉非替尼和β-石竹烯联合处理组记为组D。
具体实施方式
下面结合具体实施例对本发明做进一步的分析。
实施例1：Cell Counting Kit 8(CCK-8)检测细胞增殖
(1)细胞株的选择：
选取6种不同的细胞，分别为PC9,HCC827,HCT116,SW-1990,U251,MDA-231。上述细胞中PC9,HCC827为肺癌细胞；HCT116为结直肠癌细胞；U251为胶质瘤细胞；MDA-231为乳腺癌细胞；SW-1990为胰腺癌细胞。
选择细胞生长状态良好且处于对数生长期的六株细胞，用胰酶进行消化，加入含10％FBS的完全培养基终止，吹打成细胞悬液后转至EP管，800rpm,弃上清，加入完全培养基制成细胞悬液；
(2)使用细胞计数板计数，以每组细胞5个复孔，每孔100μL体积，不同的细胞株按照不同的细胞数接种至96孔板，并在四周边缘孔加入等量的PBS溶液，防止边缘效应。HCT116,PC9,U251按照3000个细胞接种接种至96孔板，MDA-231,SW-1990按照4000个细胞接种接种至96孔板，HCC827按照5000个细胞接种接种至96孔板。
(3)37℃、5％CO2培养箱中常规培养过夜；吸去每个孔中的液体培养基，避光条件下配制不同浓度的石竹烯药物的培养液，加入每个孔中继续培养；
(4)培养24h后，避光条件下吸去孔板中的培养液，配制实验所需要的CCK8溶液，每孔加入100μL体积(加液过程中防止气泡产生，避免酶标仪测量不准确)，培养箱中孵育1-2h；
(5)将全自动酶标仪波长调整为450nm，测定每孔的OD值；
(6)根据OD值绘制各组细胞的生长曲线，采用Graphpad 7.0计算并分析细胞增殖情况。
图1是HCC827细胞对不同浓度石竹烯药物的抑制率，其中IC50浓度为54.68μg/mL。
图2是SW-1990细胞对不同浓度石竹烯药物的抑制率，其中IC50浓度为190.2μg/mL。
图3是MDA-231细胞对不同浓度石竹烯药物的抑制率，其中IC50浓度为203.1μg/mL。
图4是HCT-116细胞对不同浓度石竹烯药物的抑制率，其中IC50浓度为104.9μg/mL。
图5是U251细胞对不同浓度石竹烯药物的抑制率，其中IC50浓度为120.1μg/mL。
图6是PC9细胞对不同浓度石竹烯药物的抑制率，其中IC50浓度为165.1μg/mL。
另外通过cck-8检测β-石竹烯与吉非替尼的协同指数。结果表明：10μM吉非替尼联合75μMβ-石竹烯时，对HCC827GR细胞有较好的抑制效果；10μM吉非替尼联合100μMβ-石竹烯时，对PC9GR细胞有较好的抑制效果。
实施例2：β-石竹烯对裸鼠皮下瘤生长的影响
选择皮下种植耐药细胞系HCC827GR，将裸鼠分为四组(每组4只)设置对照组(PBS用药剂量50mg/Kg)、吉非替尼处理组(吉非替尼的用药剂量是50mg/Kg)、β-石竹烯处理组(β-石竹烯的用药剂量是50mg/Kg)、吉非替尼和β-石竹烯联合处理组(用药剂量是50mg/Kg，其中吉非替尼与β-石竹烯的质量比为10:75)进行实验。待裸鼠成瘤5天后，进行腹腔给药以肿瘤生长天数为横坐标，肿瘤体积为纵坐标，绘制生长曲线。图7实验结果发现，吉非替尼和β-石竹烯联合处理组肿瘤体积显著小于吉非替尼处理组。因此，从体内生物学功能实验结果可以表明β-石竹烯可以逆转非小细胞肺癌细胞对吉非替尼的耐药性。
实施例3:不同药物处理组对NSCLC耐药细胞蛋白表达水平的影响
选择皮下种植耐药细胞系HCC827GR，将裸鼠分为四组(每组4只)设置对照组(PBS用药剂量50mg/Kg)、吉非替尼处理组(吉非替尼的用药剂量是50mg/Kg)、β-石竹烯处理组(β-石竹烯的用药剂量是50mg/Kg)、吉非替尼和β-石竹烯联合处理组(用药剂量是50mg/Kg，其中吉非替尼与β-石竹烯的质量比为10:75)进行实验。在20天后取瘤体提取蛋白，进行Western blot检测。
通过检测凋亡相关蛋白PARP,Bcl-2,mTOR蛋白，以及DNA损伤相关蛋白的表达，见图8。结果表明，联合加药处理组凋亡蛋白及DNA损伤均有显著的变化。其中，抗凋亡蛋白Bcl-2表达减少；凋亡相关蛋白PARP，mTOR表达增多；DNA损伤蛋白p-H2AX表达减少。以上结果表明，β-石竹烯可以通过诱导细胞凋亡逆转非小细胞肺癌细胞对吉非替尼的耐药。
上述实施例并非是对于本发明的限制，本发明并非仅限于上述实施例，只要符合本发明要求，均属于本发明的保护范围。
Claims (5)
1.β-石竹烯在制备抗肿瘤药物中的应用。
2.β-石竹烯与吉非替尼配伍的药物组合物在制备抗肿瘤药物中的应用。
3.如权利要求2所述的应用，其特征在于β-石竹烯与吉非替尼的质量比为75～100：10。
4.一种药物组合物，其特征在于包括β-石竹烯、吉非替尼、药剂学上可接受的辅料。
5.如权利要求4所述的应用，其特征在于β-石竹烯与吉非替尼的质量比为75～100：10。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111012109.3A CN113694047A (zh) | 2021-08-31 | 2021-08-31 | β-石竹烯在制备抗肿瘤药物中的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111012109.3A CN113694047A (zh) | 2021-08-31 | 2021-08-31 | β-石竹烯在制备抗肿瘤药物中的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113694047A true CN113694047A (zh) | 2021-11-26 |
Family
ID=78657940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111012109.3A Pending CN113694047A (zh) | 2021-08-31 | 2021-08-31 | β-石竹烯在制备抗肿瘤药物中的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113694047A (zh) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108025005A (zh) * | 2015-09-24 | 2018-05-11 | 博善人工智能生物科技有限公司 | 神经退行性疾病的治疗 |
-
2021
- 2021-08-31 CN CN202111012109.3A patent/CN113694047A/zh active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108025005A (zh) * | 2015-09-24 | 2018-05-11 | 博善人工智能生物科技有限公司 | 神经退行性疾病的治疗 |
Non-Patent Citations (5)
| Title |
|---|
| ANTONELLA DI SOTTO等: "Potentiation of Low-Dose Doxorubicin Cytotoxicity by Affecting P-Glycoprotein through Caryophyllane Sesquiterpenes in HepG2 Cells: An In Vitro and In Silico Study", 《INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES》 * |
| JEAN LEGAULT等: "Potentiating effect of β-caryophyllene on anticancer activity of a-humulene, isocaryophyllene and paclitaxel", 《JOURNAL OF PHARMACY AND PHARMACOLOGY》 * |
| 于熹微: "shMDR1与吉非替尼共载壳聚糖纳米粒克服肿瘤耐药的研究", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 * |
| 张季林等: "β-石竹烯生物学功能的研究进展", 《山东医药》 * |
| 杨洁等: "微电场网联合吉非替尼对肺癌细胞A549作用", 《中华实验外科杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ye et al. | Brazilein, an important immunosuppressive component from Caesalpinia sappan L. | |
| Luo et al. | Erlotinib inhibits T-cell-mediated immune response via down-regulation of the c-Raf/ERK cascade and Akt signaling pathway | |
| US20210085630A1 (en) | Pharmaceutical composition and use thereof in preparing drug for treating tumor multi-drug resistance | |
| US11116811B2 (en) | Pharmaceutical composition comprising refined indigo naturalis extracts and the use thereof | |
| Wen et al. | Initial observation on albendazole in combination with cimetidine for the treatment of human cystic echinococcosis | |
| CN1157716A (zh) | 转移抑制剂 | |
| Das et al. | mTOR signaling in cardiometabolic disease, cancer, and aging | |
| Montserrat-de la Paz et al. | Mitraphylline inhibits lipopolysaccharide-mediated activation of primary human neutrophils | |
| Bihud et al. | Goniolanceolatins A–H, cytotoxic Bis-styryllactones from Goniothalamus lanceolatus | |
| CN104398526A (zh) | 雷公藤甲素和雷公藤红素在制备抗肿瘤药物中的应用 | |
| CN102106851B (zh) | 鸦胆苦醇作为化疗药增效剂的应用 | |
| KR101591401B1 (ko) | 암 치료용 약학 조성물 | |
| WO2007073646A1 (fr) | Utilisation de 2-bromure-isovanilline pour la fabrication d'un medicament de sensibilisation a un traitement anticancereux, a une radiotherapie ou a une chimiotherapie | |
| CN102584768B (zh) | 3-硝基-8-乙氧基-2h-苯并吡喃类化合物及其制备方法与应用 | |
| CN109568313B (zh) | 一种抗肿瘤联合用药物及其在制备抗癌药物中的应用 | |
| CN113694047A (zh) | β-石竹烯在制备抗肿瘤药物中的应用 | |
| CN108295085B (zh) | 原薯蓣皂苷在制备抗耐药性骨肉瘤药物中的应用 | |
| CN109010333A (zh) | 脱氢弯孢霉素在抑制Hedgehog通路中的应用 | |
| EP3043809B1 (en) | Filipendula vulgaris extract and uses thereof | |
| KR102176602B1 (ko) | 칼슘 신호를 경유하는 엑소좀 분비 조절 기술을 이용한 항암제 병용투여용 약학적 조성물 | |
| WO2020219566A1 (en) | Combination therapeutic regimens with 1,6-dibromo-1,6-dideoxy-dulcitol | |
| CN110151748A (zh) | 一种用于治疗前列腺癌的药物组合物 | |
| CN113952343A (zh) | 隐丹参酮在抑制stat5蛋白磷酸化方面的应用 | |
| CN104825455B (zh) | 依鲁替尼的用途 | |
| CN116492321B (zh) | 一种抗肿瘤的药物组合物及应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211126 |
|
| RJ01 | Rejection of invention patent application after publication |